Pityriasis versicolor
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
non-pregnant
topical therapy
Preferred first-line therapy for all patients, especially children.[37]Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol. 1996 Feb;34(2 Pt 1):287-9.
Most topical therapies are generally equally effective, and selection is based on patient preference. Advise patients to treat the whole neck, trunk, arms, and legs down to the knees, even if only small areas are involved.[25]Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol. 2000 Mar-Apr;1(2):75-80. http://www.ncbi.nlm.nih.gov/pubmed/11702314?tool=bestpractice.com
Non-specific topical therapies are older and relatively inexpensive. These agents include pyrithione zinc, propylene glycol, and selenium sulfide.[1]Schwartz RA. Superficial fungal infections. Lancet. 2004 Sep 25-Oct 1;364(9440):1173-82. http://www.ncbi.nlm.nih.gov/pubmed/15451228?tool=bestpractice.com [14]Gupta AK, Kogan N, Batra R. Pityriasis versicolor: a review of pharmacological treatment options. Expert Opin Pharmacother. 2005 Feb;6(2):165-78. http://www.ncbi.nlm.nih.gov/pubmed/15757415?tool=bestpractice.com Selenium sulfide may cause a stinging sensation after application and some patients complain about its odour.[25]Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol. 2000 Mar-Apr;1(2):75-80. http://www.ncbi.nlm.nih.gov/pubmed/11702314?tool=bestpractice.com
Newer topical therapies include terbinafine, ciclopirox, and azole antifungals such as ketoconazole, clotrimazole, and miconazole.
Topical retinoids (e.g., tretinoin, adapalene) may also be used.[39]Mills OH Jr, Kligman AM. Letter: tretinoin in tinea versicolor. Arch Dermatol. 1974 Oct;110(4):638.[40]Shi TW, Ren XK, Yu HX, et al. Roles of adapalene in the treatment of pityriasis versicolor. Dermatology. 2012;224(2):184-8. http://www.ncbi.nlm.nih.gov/pubmed/22572567?tool=bestpractice.com
There is no benefit of one over another, other than appropriate selection of a base (i.e., for hair-bearing skin, lotions, shampoos, and solutions are better than cream-based products).
Primary options
pyrithione zinc topical: (1%) children >2 years of age and adults: apply to whole neck, trunk, arms, and legs once daily for 2 weeks
OR
propylene glycol topical: (50%) children and adults: apply to whole neck, trunk, arms, and legs twice daily for 2 weeks
OR
selenium sulfide topical: (2.5%) children and adults: apply to whole neck, trunk, arms, and legs once daily for 1 week
OR
ciclopirox topical: (0.77%) children >10 years of age and adults: apply to whole neck, trunk, arms, and legs once daily for 4 weeks
OR
ketoconazole topical: (2%) children and adults: apply to whole neck, trunk, arms, and legs once or twice daily for 2 weeks
OR
clotrimazole topical: (1%) children and adults: apply to whole neck, trunk, arms, and legs twice daily for 2 weeks
OR
miconazole topical: (2%) children and adults: apply to whole neck, trunk, arms, and legs twice daily for 2 weeks
OR
terbinafine topical: (1%) children and adults: apply to whole neck, trunk, arms, and legs twice daily for 2 weeks
OR
tretinoin topical: children ≥12 years of age and adults (0.1%) apply to whole neck, trunk, arms, and legs once daily for 2 weeks
OR
adapalene topical: children ≥12 years of age and adults (0.1%) apply to whole neck, trunk, arms, and legs once daily for 2 weeks
UV light
Additional treatment recommended for SOME patients in selected patient group
Especially in patients with hypopigmented PV, the resulting dyschromia can be long lasting, even after successful pathogen eradication. In patients with prominent hypopigmented PV, consider UV phototherapy after complete eradication of the fungus, as demonstrated by a potassium hydroxide (KOH) preparation. Re-pigmentation can be expected within 3 weeks after starting UV therapy such as UV-B 3 times weekly.[54]Jung EG, Bohnert E. Mechanism of depigmentation on pityriasis versicolor alba. Arch Dermatol Res. 1976 Oct 27;256(3):333-4.
UV-B is safe in children old enough to tolerate standing in the booth.
systemic antifungal
Primarily indicated for lesions that are extensive and resistant to topical therapy, and for patients who are immunosuppresed, experience frequent relapses, and have difficulty complying with topical therapies, as they are more convenient and less time consuming to use.[14]Gupta AK, Kogan N, Batra R. Pityriasis versicolor: a review of pharmacological treatment options. Expert Opin Pharmacother. 2005 Feb;6(2):165-78. http://www.ncbi.nlm.nih.gov/pubmed/15757415?tool=bestpractice.com
Used only for short time periods to minimise the risk of adverse effects.[25]Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol. 2000 Mar-Apr;1(2):75-80. http://www.ncbi.nlm.nih.gov/pubmed/11702314?tool=bestpractice.com
Systemic agents include fluconazole, itraconazole, or ketoconazole.[7]Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol. 2002 Jan;16(1):19-33. http://www.ncbi.nlm.nih.gov/pubmed/11952286?tool=bestpractice.com [13]Gupta AK, Batra R, Bluhm R, et al. Skin diseases associated with Malassezia species. J Am Acad Dermatol. 2004 Nov;51(5):785-98. http://www.ncbi.nlm.nih.gov/pubmed/15523360?tool=bestpractice.com [14]Gupta AK, Kogan N, Batra R. Pityriasis versicolor: a review of pharmacological treatment options. Expert Opin Pharmacother. 2005 Feb;6(2):165-78. http://www.ncbi.nlm.nih.gov/pubmed/15757415?tool=bestpractice.com [20]Thoma W, Kramer HJ, Mayser P. Pityriasis versicolor alba. J Eur Acad Dermatol Venereol. 2005 Mar;19(2):147-52. http://www.ncbi.nlm.nih.gov/pubmed/15752280?tool=bestpractice.com [43]Kokturk A, Kaya TI, Ikizoglu G, et al. Efficacy of three short-term regimens of itraconazole in the treatment of pityriasis versicolor. J Dermatolog Treat. 2002 Dec;13(4):185-7. http://www.ncbi.nlm.nih.gov/pubmed/19753739?tool=bestpractice.com [44]Gupta AK, Lane D, Paquet M. Systematic review of systemic treatments for tinea versicolor and evidence-based dosing regimen recommendations. J Cutan Med Surg. 2014 Mar-Apr;18(2):79-90. http://www.ncbi.nlm.nih.gov/pubmed/24636433?tool=bestpractice.com Systemic azole antifungals differ little in efficacy.[7]Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol. 2002 Jan;16(1):19-33. http://www.ncbi.nlm.nih.gov/pubmed/11952286?tool=bestpractice.com However, the safety and efficacy of oral itraconazole has not been established in children. While studies have failed to consistently demonstrate the efficacy of a single dose of itraconazole in the treatment of PV, there is some evidence to suggest that a short course of itraconazole may be as effective as a multi-day course of treatment.[43]Kokturk A, Kaya TI, Ikizoglu G, et al. Efficacy of three short-term regimens of itraconazole in the treatment of pityriasis versicolor. J Dermatolog Treat. 2002 Dec;13(4):185-7. http://www.ncbi.nlm.nih.gov/pubmed/19753739?tool=bestpractice.com [45]Köse O, Bülent Taştan H, Riza Gür A, et al. Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea versicolor. J Dermatolog Treat. 2002 Jun;13(2):77-9. http://www.ncbi.nlm.nih.gov/pubmed/12060506?tool=bestpractice.com [46]Wahab MA, Ali ME, Rahman MH, et al. Single dose (400 mg) versus 7 day (200 mg) daily dose itraconazole in the treatment of tinea versicolor: a randomized clinical trial. Mymensingh Med J. 2010 Jan;19(1):72-6. http://www.ncbi.nlm.nih.gov/pubmed/20046175?tool=bestpractice.com Ketoconazole may cause severe liver injury and adrenal insufficiency. In July 2013, the European Medicines Agency’s Committee on Medicinal Products for Human Use (CHMP) recommended that oral ketoconazole should not be used for the treatment of fungal infections, as the benefits of treatment no longer outweigh the risks. As a consequence of this, oral ketoconazole may be unavailable or restricted in some countries.[47]Medicines and Healthcare Products Regulatory Agency. Press release: oral ketoconazole-containing medicines should no longer be used for fungal infections. July 2013 [internet publication]. http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON297530 [48]European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. July 2013 [internet publication]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001855.jsp&mid=WC0b01ac058004d5c1 Its use is contraindicated in patients with liver disease. If used, monitor liver and adrenal function before and during treatment.[49]US Food and Drug Administration. FDA drug safety communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. May 2016 [internet publication]. http://www.fda.gov/Drugs/DrugSafety/ucm362415.htm
Resistance to traditional systemic agents such as itraconazole and fluconazole has been described, which may necessitate higher doses and longer courses of these medications, or primary use of older topical treatments such as selenium sulfide and pyrithione zinc.[50]Helou J, Obeid G, Moutran R, et al. Pityriasis versicolor: a case of resistance to treatment. Int J Dermatol. 2014 Feb;53(2):e114-6.
Oral terbinafine and griseofulvin are ineffective in treating PV.[7]Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol. 2002 Jan;16(1):19-33. http://www.ncbi.nlm.nih.gov/pubmed/11952286?tool=bestpractice.com
As systemic azole antifungals are best absorbed in an acid environment, they should be taken with a carbonated beverage. To increase delivery of the medication to its site of action in the stratum corneum, patients can take it 45 minutes prior to working out to a sweat, and then waiting several hours before having a shower.
Primary options
fluconazole: children: 3-6 mg/kg orally once weekly for 2 weeks; adults: 400 mg orally as a single dose, or 200 mg once weekly for 2 weeks
OR
itraconazole: adults: 400 mg orally once daily for 3 days, or 200 mg orally once daily for 7 days
Secondary options
ketoconazole: children >2 years of age: consult specialist for guidance on dose; adults: 400 mg orally once weekly for 2 weeks
UV light
Additional treatment recommended for SOME patients in selected patient group
Especially in patients with hypopigmented PV, the resulting dyschromia can be long lasting, even after successful pathogen eradication. In patients with prominent hypopigmented PV, consider UV phototherapy after complete eradication of the fungus, as demonstrated by a KOH preparation. Repigmentation can be expected within 3 weeks after starting UV therapy such as UV-B 3 times weekly.[54]Jung EG, Bohnert E. Mechanism of depigmentation on pityriasis versicolor alba. Arch Dermatol Res. 1976 Oct 27;256(3):333-4.
UV-B is safe in children old enough to tolerate standing in the booth.
pregnant
topical therapy
Most topical therapies are generally equally effective and selection is based on patient preference. Advise patients to treat the whole neck, trunk, arms, and legs down to the knees, even if only small areas are involved.[25]Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol. 2000 Mar-Apr;1(2):75-80. http://www.ncbi.nlm.nih.gov/pubmed/11702314?tool=bestpractice.com
Non-specific topical therapies are older and relatively inexpensive. Pyrithione zinc and propylene glycol have not been adequately tested in pregnant women. However, no teratogenicity or embryotoxicity has been observed in the offspring of laboratory animals treated with pyrithione zinc, and there have been no documented problems in humans.[41]Wedig JH, Kennedy GL Jr, Jenkins DH, et al. Teratologic evaluation of dermally applied zinc pyrithione on swine. Toxicol Appl Pharmacol. 1976 May;36(2):255-9.[42]Nolen GA, Patrick LF, Dierckman TA. A percutaneous teratology study of zinc pyrithione in rabbits. Toxicol Appl Pharmacol. 1975 Mar;31(3):430-3. http://www.ncbi.nlm.nih.gov/pubmed/1145628?tool=bestpractice.com
There is inadequate data to support the use of terbinafine or ciclopirox in pregnant women; however, no teratogenicity or embryotoxicity has been observed in animal studies with either drug.
Selenium sulfide and the topical azole antifungals are generally not recommended in pregnancy. However, some clinicians still use selenium sulfide, topically during pregnancy.
Primary options
pyrithione zinc topical: (1%) adults: apply to whole neck, trunk, arms, and legs once daily for 2 weeks
OR
propylene glycol topical: (50%) adults: apply to whole neck, trunk, arms, and legs twice daily for 2 weeks
Secondary options
ciclopirox topical: (0.77%) adults: apply to whole neck, trunk, arms, and legs once daily for 4 weeks
OR
terbinafine topical: (1%) children and adults: apply to whole neck, trunk, arms, and legs twice daily for 2 weeks
UV light
Additional treatment recommended for SOME patients in selected patient group
Especially in patients with hypopigmented PV, the resulting dyschromia can be long lasting, even after successful pathogen eradication. In patients with prominent hypopigmented PV, consider UV phototherapy after complete eradication of the fungus, as demonstrated by a KOH preparation. Re-pigmentation can be expected within 3 weeks after starting UV therapy such as UV-B 3 times weekly.[54]Jung EG, Bohnert E. Mechanism of depigmentation on pityriasis versicolor alba. Arch Dermatol Res. 1976 Oct 27;256(3):333-4. UV-B is safe in pregnant women.
recurrent disease after successful pathogen eradication
prophylactic topical or systemic antifungal
In patients with recurrent disease, prophylactic treatment may be necessary after a successful treatment course.
First-line prophylactic treatment, especially in children, is selenium sulfide.[1]Schwartz RA. Superficial fungal infections. Lancet. 2004 Sep 25-Oct 1;364(9440):1173-82. http://www.ncbi.nlm.nih.gov/pubmed/15451228?tool=bestpractice.com
If topical prophylactic therapy is ineffective, second-line therapies include pulse-dosed oral azole antifungals.[51]Faergemann J, Djarv L. Tinea versicolor: treatment and prophylaxis with ketoconazole. Cutis. 1982 Oct;30(4):542-5;550.[52]Rausch LJ, Jacobs PH. Tinea versicolor: treatment and prophylaxis with monthly administration of ketoconazole. Cutis. 1984 Nov;34(5):470-1. http://www.ncbi.nlm.nih.gov/pubmed/6094116?tool=bestpractice.com [53]Faergemann J, Gupta AK, Al Mofadi A, et al. Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch Dermatol. 2002 Jan;138(1):69-73. http://archderm.ama-assn.org/cgi/content/full/138/1/69 http://www.ncbi.nlm.nih.gov/pubmed/11790169?tool=bestpractice.com The safety and efficacy of oral itraconazole has not been established in children. Ketoconazole may cause severe liver injury and adrenal insufficiency. In July 2013, the European Medicines Agency’s Committee on Medicinal Products for Human Use (CHMP) recommended that oral ketoconazole should not be used for the treatment of fungal infections, as the benefits of treatment no longer outweigh the risks. As a consequence of this, oral ketoconazole may be unavailable or restricted in some countries.[47]Medicines and Healthcare Products Regulatory Agency. Press release: oral ketoconazole-containing medicines should no longer be used for fungal infections. July 2013 [internet publication]. http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON297530 [48]European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. July 2013 [internet publication]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001855.jsp&mid=WC0b01ac058004d5c1 Its use is contraindicated in patients with liver disease. If used, monitor liver and adrenal function before and during treatment.[49]US Food and Drug Administration. FDA drug safety communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. May 2016 [internet publication]. http://www.fda.gov/Drugs/DrugSafety/ucm362415.htm
As systemic azole antifungals are best absorbed in an acid environment, they should be taken with a carbonated beverage.
Primary options
selenium sulfide topical: (2.5%) children and adults: apply to whole neck, trunk, arms, and legs on the first and third day of each month for 6 months
Secondary options
ketoconazole: children >2 years of age: consult specialist for guidance on dose; adults: 400 mg orally once monthly for 6 months, or 200 mg once daily for 3 days at the beginning of each month for 6 months
OR
itraconazole: adults: 400 mg orally once monthly for 6 months
topical pyrithione zinc
In patients with recurrent disease, prophylactic treatment may be necessary after a successful treatment course. First-line prophylactic treatment in pregnant women is pyrithione zinc.
Primary options
pyrithione zinc topical: (1%) adults: apply to whole neck, trunk, arms and legs on the first and third day of each month for 6 months
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer